P1389: RUXOLITINIB DEMONSTRATES A GREATER CORTICOSTEROID-SPARING EFFECT THAN BEST AVAILABLE THERAPY IN PATIENTS WITH CORTICOSTEROID-REFRACTORY/DEPENDENT CHRONIC GRAFT-VS-HOST DISEASE. (23rd June 2022) - Zeiser, R.; Russo, D.; Ram, R.; Hashmi, S.; Chakraverty, R.; Moritz Middeke, J.; Giebel, S.; Sarkar, R.; Gowda, M.; Gunes, S.; Stefanelli, T.; Lee, S. J.; et al.